Bio-Techne Corporation (TECH) 10-Year Financial Performance & Capital Metrics

TECH • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.Show more

Revenue $1.22B +5.2%
EBITDA $212M -33.4%
Net Income $73M -56.3%
EPS (Diluted) 0.46 -56.2%
Gross Margin 64.8% -2.4%
EBITDA Margin 17.4% -36.7%
Operating Margin 8.38% -53.0%
Net Margin 6.02% -58.5%
ROE 3.68% -55.8%
ROIC 3.38% -50.1%
Debt/Equity 0.23 +14.1%
Interest Coverage 12.02 -8.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 21.0% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.5%
✓Healthy 5Y average net margin of 17.1%

✗Weaknesses

✗Profits declining 20.4% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y10.43%

5Y10.55%

3Y3.33%

TTM3.85%

Profit (Net Income) CAGR

10Y-3.76%

5Y-20.37%

3Y-35.38%

TTM-48.26%

EPS CAGR

10Y-4.38%

5Y-20.52%

3Y-34.8%

TTM-47.87%

ROCE

10Y Avg10.05%

5Y Avg10.21%

3Y Avg8.42%

Latest4.15%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	499.02M	563M	642.99M	714.01M	738.69M	931.03M	1.11B	1.14B	1.16B	1.22B
Revenue Growth %	0.1%	0.13%	0.14%	0.11%	0.03%	0.26%	0.19%	0.03%	0.02%	0.05%
Cost of Goods Sold+	162.36M	188.46M	210.85M	240.51M	255.5M	298.18M	349.1M	366.89M	389.33M	429.36M
COGS % of Revenue	0.33%	0.33%	0.33%	0.34%	0.35%	0.32%	0.32%	0.32%	0.34%	0.35%
Gross Profit+	336.66M	374.54M	432.14M	473.49M	483.19M	632.85M	756.5M	769.82M	769.73M	790.27M
Gross Margin %	0.67%	0.67%	0.67%	0.66%	0.65%	0.68%	0.68%	0.68%	0.66%	0.65%
Gross Profit Growth %	0.1%	0.11%	0.15%	0.1%	0.02%	0.31%	0.2%	0.02%	-0%	0.03%
Operating Expenses+	186.07M	252.76M	295.96M	326.77M	325.77M	395.55M	459.91M	470.87M	563.04M	688.02M
OpEx % of Revenue	0.37%	0.45%	0.46%	0.46%	0.44%	0.42%	0.42%	0.41%	0.49%	0.56%
Selling, General & Admin	140.88M	199.24M	240.64M	264.36M	240.88M	289.92M	339M	352.44M	393.32M	415.1M
SG&A % of Revenue	0.28%	0.35%	0.37%	0.37%	0.33%	0.31%	0.31%	0.31%	0.34%	0.34%
Research & Development	45.19M	53.51M	55.33M	62.41M	65.19M	70.6M	87.14M	92.49M	96.66M	99.5M
R&D % of Revenue	0.09%	0.1%	0.09%	0.09%	0.09%	0.08%	0.08%	0.08%	0.08%	0.08%
Other Operating Expenses	0	0	0	0	19.7M	35.03M	33.77M	25.94M	73.06M	173.42M
Operating Income+	150.59M	121.78M	136.18M	125.58M	157.42M	237.3M	296.59M	298.94M	206.69M	102.25M
Operating Margin %	0.3%	0.22%	0.21%	0.18%	0.21%	0.25%	0.27%	0.26%	0.18%	0.08%
Operating Income Growth %	0.02%	-0.19%	0.12%	-0.08%	0.25%	0.51%	0.25%	0.01%	-0.31%	-0.51%
EBITDA+	193.36M	181.82M	200.64M	203.75M	240.16M	325.04M	397.66M	406.18M	318.4M	212.16M
EBITDA Margin %	0.39%	0.32%	0.31%	0.29%	0.33%	0.35%	0.36%	0.36%	0.27%	0.17%
EBITDA Growth %	0.05%	-0.06%	0.1%	0.02%	0.18%	0.35%	0.22%	0.02%	-0.22%	-0.33%
D&A (Non-Cash Add-back)	42.76M	60.04M	64.46M	78.17M	82.74M	87.75M	101.07M	107.24M	111.71M	109.9M
EBIT	149.23M	119.32M	136.14M	133.72M	295.67M	162.13M	312.69M	349.87M	201.43M	106.97M
Net Interest Income+	-1.5M	-7.06M	-9.78M	-21.14M	-18.59M	-13.48M	-10.52M	-7.8M	-12.41M	-4.62M
Interest Income	249K	304K	409K	569K	605K	473K	794K	3.41M	3.32M	3.89M
Interest Expense	1.75M	7.36M	10.19M	21.7M	19.2M	13.95M	11.31M	11.21M	15.74M	8.51M
Other Income/Expense	-3.11M	-8.62M	-10.23M	-34.7M	119.06M	-89.12M	4.8M	39.72M	-21M	-3.79M
Pretax Income+	147.48M	113.16M	125.95M	112.02M	276.48M	148.18M	301.39M	338.66M	185.69M	98.46M
Pretax Margin %	0.3%	0.2%	0.2%	0.16%	0.37%	0.16%	0.27%	0.3%	0.16%	0.08%
Income Tax+	43.01M	35.88M	-602K	15.94M	47.18M	8.59M	38.29M	53.22M	17.58M	25.06M
Effective Tax Rate %	0.71%	0.68%	1%	0.86%	0.83%	0.95%	0.9%	0.84%	0.91%	0.75%
Net Income+	104.48M	77.29M	125.35M	96.07M	229.3M	140.41M	272.05M	285.26M	168.1M	73.4M
Net Margin %	0.21%	0.14%	0.19%	0.13%	0.31%	0.15%	0.25%	0.25%	0.15%	0.06%
Net Income Growth %	-0.03%	-0.26%	0.62%	-0.23%	1.39%	-0.39%	0.94%	0.05%	-0.41%	-0.56%
Net Income (Continuing)	104.48M	76.09M	126.15M	96.07M	229.3M	139.59M	263.1M	285.44M	168.1M	73.4M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	8.26M	-759K	0	0	0
EPS (Diluted)+	0.70	0.52	0.82	0.62	1.45	0.87	1.66	1.76	1.05	0.46
EPS Growth %	-0.03%	-0.26%	0.58%	-0.24%	1.34%	-0.4%	0.91%	0.06%	-0.4%	-0.56%
EPS (Basic)	0.70	0.52	0.84	0.64	1.50	0.91	1.73	1.81	1.07	0.47
Diluted Shares Outstanding	149.3M	150M	152.22M	155.57M	157.6M	161.93M	164.12M	161.85M	160.77M	159.72M
Basic Shares Outstanding	148.78M	149.25M	149.9M	151.12M	152.8M	154.99M	156.88M	157.18M	157.71M	157.52M
Dividend Payout Ratio	0.46%	0.61%	0.38%	0.5%	0.21%	0.35%	0.18%	0.18%	0.3%	0.69%

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	253.89M	345.26M	398.37M	412.61M	520.92M	510.61M	605.56M	621.48M	617.42M	608.3M
Cash & Short-Term Investments	95.83M	157.71M	181.75M	166.03M	270.89M	231.55M	247.03M	204.31M	152.86M	162.19M
Cash Only	64.24M	91.61M	121.99M	100.89M	146.63M	199.09M	172.57M	180.57M	151.79M	162.19M
Short-Term Investments	31.6M	66.1M	59.76M	65.15M	124.27M	32.46M	74.46M	23.74M	1.07M	0
Accounts Receivable	93.39M	116.83M	120.3M	137.47M	122.53M	145.38M	194.55M	218.47M	241.39M	206.88M
Days Sales Outstanding	68.31	75.74	68.29	70.27	60.55	57	64.23	70.15	76.02	61.91
Inventory	57.1M	60.15M	85.65M	91.05M	103.15M	116.75M	141.12M	171.64M	179.73M	189.45M
Days Inventory Outstanding	128.37	116.5	148.26	138.18	147.36	142.91	147.55	170.76	168.5	161.05
Other Current Assets	7.56M	13.33M	10.67M	18.06M	24.34M	16.92M	22.86M	27.07M	43.43M	49.79M
Total Non-Current Assets+	875.62M	1.21B	1.19B	1.47B	1.51B	1.75B	1.69B	2.02B	2.09B	1.95B
Property, Plant & Equipment	132.36M	135.12M	145.35M	154.04M	248.29M	281.74M	288.8M	324.53M	342.44M	319.12M
Fixed Asset Turnover	3.77x	4.17x	4.42x	4.64x	2.98x	3.30x	3.83x	3.50x	3.38x	3.82x
Goodwill	430.88M	579.03M	597.89M	732.67M	728.31M	843.07M	822.1M	872.74M	972.66M	980.93M
Intangible Assets	310.52M	452.04M	446.33M	579.43M	516.54M	615.97M	531.52M	534.64M	507.08M	365.6M
Long-Term Investments	-62.84M	40.38M	2.66M	-89.75M	0	0	0	255.86M	242.34M	250.98M
Other Non-Current Assets	1.92M	-116.98M	-83.69M	5.67M	13.52M	11.57M	46.83M	29.45M	21.93M	22.63M
Total Assets+	1.13B	1.56B	1.59B	1.88B	2.03B	2.26B	2.29B	2.64B	2.7B	2.56B
Asset Turnover	0.44x	0.36x	0.40x	0.38x	0.36x	0.41x	0.48x	0.43x	0.43x	0.48x
Asset Growth %	0.06%	0.38%	0.02%	0.18%	0.08%	0.12%	0.01%	0.15%	0.02%	-0.05%
Total Current Liabilities+	54.15M	135.36M	78.69M	101.98M	106.67M	152.28M	176.02M	128.51M	159.38M	175.85M
Accounts Payable	20.65M	16.86M	18.45M	16.21M	23.09M	29.38M	33.87M	25.68M	37.97M	25.31M
Days Payables Outstanding	46.43	32.65	31.94	24.6	32.99	35.97	35.41	25.55	35.59	21.52
Short-Term Debt	3.76M	0	0	12.5M	12.5M	12.5M	12.5M	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	1.78M	65.1M	21.4M	3.4M	0	3.89M	1.24M	1.41M	2.15M	1.65M
Current Ratio	4.69x	2.55x	5.06x	4.05x	4.88x	3.35x	3.44x	4.84x	3.87x	3.46x
Quick Ratio	3.63x	2.11x	3.97x	3.15x	3.92x	2.59x	2.64x	3.50x	2.75x	2.38x
Cash Conversion Cycle	150.25	159.59	184.61	183.85	174.92	163.94	176.37	215.36	208.92	201.44
Total Non-Current Liabilities+	196.08M	470.47M	435.37M	616.84M	539.73M	539.44M	417.78M	543.67M	475.64M	463.21M
Long-Term Debt	91.5M	343.77M	339M	492.66M	344.24M	328.83M	243.41M	350M	319M	346M
Capital Lease Obligations	0	0	0	0	67.25M	67.63M	58.13M	93.77M	87.62M	83.96M
Deferred Tax Liabilities	62.76M	118M	86.29M	89.75M	101.09M	93.13M	98.99M	88.98M	55.86M	6.17M
Other Non-Current Liabilities	104.65M	129.3M	9.34M	124.18M	27.15M	49.86M	17.24M	10.92M	13.16M	27.08M
Total Liabilities	250.23M	605.83M	514.06M	718.82M	646.4M	691.72M	593.79M	672.18M	635.02M	639.06M
Total Debt+	133.76M	349.9M	339M	505.16M	433.53M	420.55M	325.97M	454.96M	419.54M	444.06M
Net Debt	69.52M	258.29M	217.01M	404.27M	286.9M	221.46M	153.4M	274.39M	267.75M	281.87M
Debt / Equity	0.15x	0.37x	0.31x	0.43x	0.31x	0.27x	0.19x	0.23x	0.20x	0.23x
Debt / EBITDA	0.69x	1.92x	1.69x	2.48x	1.81x	1.29x	0.82x	1.12x	1.32x	2.09x
Net Debt / EBITDA	0.36x	1.42x	1.08x	1.98x	1.19x	0.68x	0.39x	0.68x	0.84x	1.33x
Interest Coverage	86.15x	16.54x	13.37x	5.79x	8.20x	17.01x	26.23x	26.66x	13.13x	12.02x
Total Equity+	879.28M	950.83M	1.08B	1.17B	1.38B	1.57B	1.7B	1.97B	2.07B	1.92B
Equity Growth %	0.04%	0.08%	0.13%	0.08%	0.18%	0.14%	0.08%	0.16%	0.05%	-0.07%
Book Value per Share	5.89	6.34	7.09	7.49	8.76	9.70	10.36	12.15	12.87	12.01
Total Shareholders' Equity	879.28M	950.83M	1.08B	1.17B	1.38B	1.56B	1.7B	1.97B	2.07B	1.92B
Common Stock	372K	374K	376K	379K	385K	390K	1.57M	1.58M	1.58M	1.55M
Retained Earnings	770.55M	799.03M	876.93M	931.93M	1.06B	1.09B	1.12B	1.31B	1.33B	1.07B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-70.41M	-48.94M	-44.81M	-83.52M	-97.2M	-57.29M	-75.2M	-66.06M	-78.32M	-59.88M
Minority Interest	0	0	0	0	0	8.26M	-759K	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	143.87M	143.45M	170.37M	181.62M	205.22M	352.16M	325.27M	254.39M	298.98M	287.56M
Operating CF Margin %	0.29%	0.25%	0.26%	0.25%	0.28%	0.38%	0.29%	0.22%	0.26%	0.24%
Operating CF Growth %	0.03%	-0%	0.19%	0.07%	0.13%	0.72%	-0.08%	-0.22%	0.18%	-0.04%
Net Income	104.48M	76.09M	126.15M	96.07M	229.3M	139.59M	263.1M	285.44M	168.07M	73.4M
Depreciation & Amortization	42.76M	60.04M	64.46M	78.17M	82.74M	87.75M	101.07M	107.24M	111.71M	109.9M
Stock-Based Compensation	9.43M	14.63M	28.24M	32.28M	32.37M	48.98M	42.18M	39.23M	38.04M	40.83M
Deferred Taxes	-2.62M	-3.43M	-46.72M	-13.58M	13.13M	-27.43M	6.82M	-29.57M	-39.45M	-51.11M
Other Non-Cash Items	4.87M	10.06M	-3.67M	16.43M	-147.07M	74.02M	-18.38M	-57.37M	30.68M	102.99M
Working Capital Changes	-15.04M	-13.93M	1.9M	-27.75M	-5.25M	29.26M	-69.52M	-90.58M	-10.11M	11.54M
Change in Receivables	-217.08M	-19.69M	-308.66M	-2.7M	6.56M	-15.55M	-57.6M	-23.36M	-20.53M	42.6M
Change in Inventory	-6.63M	-732K	-13.33M	-13.65M	-14.86M	-7.14M	-32.01M	-30.17M	-14.21M	-18.14M
Change in Payables	8.92M	5.7M	5.03M	6.1M	10.34M	19.09M	12.74M	-7.91M	25.77M	-13.95M
Cash from Investing+	-107.57M	-305.95M	-38.71M	-336.8M	27.09M	-243.52M	-96.85M	-265.65M	-203.03M	-35.18M
Capital Expenditures	-16.9M	-15.18M	-20.93M	-25.41M	-51.74M	-44.3M	-44.91M	-38.24M	-62.88M	-31.01M
CapEx % of Revenue	0.03%	0.03%	0.03%	0.04%	0.07%	0.05%	0.04%	0.03%	0.05%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-25K	-36.99M	680K	-21.9M	0	0	-53M	-232M	7M	9.74M
Cash from Financing+	-23.08M	189.39M	-99.19M	134.38M	-183.8M	-62.55M	-242.85M	22.62M	-122.4M	-253.91M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-47.61M	-47.33M	-47.97M	-48.36M	-48.9M	-49.62M	-50.19M	-50.28M	-50.42M	-50.39M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	6.02M	-15.56M	-46.72M	31.65M	63.71M	45.75M	53.78M	-1.54M	39.06M	45.22M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	126.97M	128.27M	149.43M	156.21M	153.47M	307.86M	280.36M	216.15M	236.1M	256.55M
FCF Margin %	0.25%	0.23%	0.23%	0.22%	0.21%	0.33%	0.25%	0.19%	0.2%	0.21%
FCF Growth %	0.06%	0.01%	0.16%	0.05%	-0.02%	1.01%	-0.09%	-0.23%	0.09%	0.09%
FCF per Share	0.85	0.86	0.98	1.00	0.97	1.90	1.71	1.34	1.47	1.61
FCF Conversion (FCF/Net Income)	1.38x	1.86x	1.36x	1.89x	0.89x	2.51x	1.20x	0.89x	1.78x	3.92x
Interest Paid	1.66M	7.45M	9.84M	21.5M	18.61M	13.58M	11.03M	8.37M	14.5M	18.95M
Taxes Paid	44.9M	42.9M	35.08M	36.81M	41.99M	20.95M	30.34M	88.43M	65.25M	74.36M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	12.1%	8.45%	12.35%	8.56%	18.01%	9.51%	16.63%	15.56%	8.33%	3.68%
Return on Invested Capital (ROIC)	12.16%	8.47%	8.15%	6.57%	7.29%	10.29%	12.2%	10.95%	6.77%	3.38%
Gross Margin	67.46%	66.53%	67.21%	66.31%	65.41%	67.97%	68.42%	67.72%	66.41%	64.8%
Net Margin	20.94%	13.73%	19.49%	13.46%	31.04%	15.08%	24.61%	25.1%	14.5%	6.02%
Debt / Equity	0.15x	0.37x	0.31x	0.43x	0.31x	0.27x	0.19x	0.23x	0.20x	0.23x
Interest Coverage	86.15x	16.54x	13.37x	5.79x	8.20x	17.01x	26.23x	26.66x	13.13x	12.02x
FCF Conversion	1.38x	1.86x	1.36x	1.89x	0.89x	2.51x	1.20x	0.89x	1.78x	3.92x
Revenue Growth	10.34%	12.82%	14.21%	11.04%	3.46%	26.04%	18.75%	2.81%	1.97%	5.23%

Revenue by Segment

	2012	2013	2014	2023	2024	2025
Consumables	-	-	-	917.73M	928.18M	972.29M
Consumables Growth	-	-	-	-	1.14%	4.75%
Instruments	-	-	-	112.08M	108.27M	112.09M
Instruments Growth	-	-	-	-	-3.40%	3.52%
Royalty	-	-	-	21.1M	23.34M	23.69M
Royalty Growth	-	-	-	-	10.64%	1.49%
Biotechnology	293.27M	288.16M	300.58M	-	-	-
Biotechnology Growth	-	-1.75%	4.31%	-	-	-
Clinical Controls	-	22.42M	57.19M	-	-	-
Clinical Controls Growth	-	-	155.07%	-	-	-
Hematology	21.29M	-	-	-	-	-
Hematology Growth	-	-	-	-	-	-

Revenue by Geography

	2012	2013	2014	2023	2024	2025
U S	172.31M	164.31M	190.36M	642.47M	657.75M	683.23M
U S Growth	-	-4.64%	15.85%	237.50%	2.38%	3.87%
Europe	90.14M	88.3M	97.16M	220.23M	241.43M	266.31M
Europe Growth	-	-2.05%	10.03%	126.67%	9.63%	10.30%
C N	11.38M	14.11M	18.88M	113.87M	99.47M	100.46M
C N Growth	-	23.98%	33.83%	503.18%	-12.65%	1.00%
APAC, excluding China	-	-	-	73.19M	73.9M	77.26M
APAC, excluding China Growth	-	-	-	-	0.98%	4.55%
UNITED KINGDOM	-	-	-	-	-	54.83M
UNITED KINGDOM Growth	-	-	-	-	-	-
Rest Of World	14.74M	15.26M	18.66M	37.49M	36.5M	37.55M
Rest Of World Growth	-	3.49%	22.35%	100.87%	-2.65%	2.87%
United Kingdom	-	-	-	49.46M	50.01M	-
United Kingdom Growth	-	-	-	-	1.12%	-
Other Asia	25.99M	28.61M	32.7M	-	-	-
Other Asia Growth	-	10.08%	14.32%	-	-	-

Frequently Asked Questions

Valuation & Price

Bio-Techne Corporation (TECH) has a price-to-earnings (P/E) ratio of 152.1x. This suggests investors expect higher future growth.

Growth & Financials

Bio-Techne Corporation (TECH) reported $1.22B in revenue for fiscal year 2025. This represents a 287% increase from $314.6M in 2012.

Bio-Techne Corporation (TECH) grew revenue by 5.2% over the past year. This is steady growth.

Yes, Bio-Techne Corporation (TECH) is profitable, generating $78.0M in net income for fiscal year 2025 (6.0% net margin).

Dividend & Returns

Yes, Bio-Techne Corporation (TECH) pays a dividend with a yield of 0.45%. This makes it attractive for income-focused investors.

Bio-Techne Corporation (TECH) has a return on equity (ROE) of 3.7%. This is below average, suggesting room for improvement.

Bio-Techne Corporation (TECH) generated $224.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...